Showing 8121-8130 of 10543 results for "".
- Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasishttps://practicaldermatology.com/news/envudeucitinib-enables-durable-treat-to-target-control-in-plaque-psoriasis/2485542/Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasi
- Rezpegaldesleukin Demonstrates Broad Phase 2b Efficacy in Atopic Dermatitis and Asthmahttps://practicaldermatology.com/news/rezpegaldesleukin-demonstrates-broad-phase-2b-efficacy-in-atopic-dermatitis-and-asthma/2485541/Rezpegaldesleukin significantly improved disease severity, itch, and asthma-related symptoms in patients with moderate-to-severe atopic dermatitis, according to “Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in a Phase 2b Trial,” a poster by
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- Analysis: Chronic Hand Eczema Affects 1 in 10 Adultshttps://practicaldermatology.com/news/chronic-hand-eczema-affects-1-in-10-adults-study-finds/2485383/A cross-sectional study of over 10,000 U.S. adults indicates chronic hand eczema (CHE) is more common than previously estimated, with nearly 1 in 10 reporting a physician diagnosis. The data, presented in a poster by Raj Chovati
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<
- Review: Wide Variability in Dermatology ICD Code Validityhttps://practicaldermatology.com/news/review-wide-variability-in-dermatology-icd-code-validity/2485230/A systematic review published in JAMA Dermatology showed wide variability in the accuracy of International Classification of Diseases (ICD) codes used to identify dermatologic conditions in U.S. administrative datasets.
- GLP-1RAs Linked with Reduced Itch Prevalence in Diabetes Cohorthttps://practicaldermatology.com/news/glp-1-receptor-agonists-tied-to-reduced-itch-prevalence-in-diabetes-cohort/2485184/Results from a new retrospective cohort analysis suggest some glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a reduced prevalence of itch the type 2 diabetes mellitus (T2DM), independent of glycemic control.
- Discrimination, Language Gaps Undermine HS Care for Latine Adults: Analysishttps://practicaldermatology.com/news/latine-patients-with-hs-face-barriers-in-pain-and-wound-care-study-finds-discrimination-language-gaps-undermine-hs-care-for-latine-adults/2485130/Latine patients with hidradenitis suppurativa (HS) continue to face barriers to care, according to a qualitative study published in JAMA Dermatology. Study researchers analyzed transcripts from semistructured interviews
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to